Mabion Company Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.

The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases.

It also offers clinical and commercial drug substance manufacturing of therapeutic proteins using mammalian and insect cell cultures, including biosimilars, monoclonals, vaccine antigens, and other recombinant proteins.

Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.

Mabion S.A.

Country	Poland
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	213
CEO	Krzysztof Kaczmarczyk

Contact Details

Address: ul. gen. Mariana Langiewicza 60 Konstantynów Lódzki, 95-050 Poland
Phone	48 42 207 7890
Website	mabion.eu

Stock Details

Ticker Symbol	MAB
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLMBION00016
SIC Code	2836

Key Executives

Name	Position
Krzysztof Kaczmarczyk	Chief Executive Officer and President of Management Board
Grzegorz Grabowicz	Chief Financial Officer, Financial Director and Member of Management Board
Dr. Slawomir Jaros EMBA, Eng., Ph.D.	Member of the Management Board and Scientific and Quality Director
Adam Pietruszkiewicz	Member of Management Board and Business Development Director
Julita Balcerek M.D.	Member of the Management Board, Operations Director and Chief Operating Officer
Aneta Turek	Chief Accountant
Pawel Pobiedzinski	Head of Logistics and Procurement
Joanna Krolasik	Head of Microbiology Laboratory